CHRS coherus.com Earnings per share for the last twelve months

CHRS (Coherus) - company brandmark

The reliability of Coherus Biosciences (CHRS) is underscored by regulator-approved drugs and proprietary manufacturing facilities in the US. This GURU.Markets chart of the TTM net income per share reflects price stability, with the value -1.02 serving as the target level. Financial resilience is based on the exclusive B2B distribution of Loqtorzi to oncology centers and seamless production outsourcing via certified vendors, which eliminates raw material risks.

CHRS (Coherus BioSciences) Net earnings per share for the last 12 months history from 07/04/2022 to 11/10/2026

Coherus - analytical breakdowns and key metrics (CHRS)

- current quotes and average value forecast:
Price Chart Coherus BioSciences, Inc.|CHRS - Average Forecast Price
- market capitalization data:
Market Value Coherus BioSciences, Inc.|CHRS - Business Value
- shareholders' equity book value data:
Book Value per Share Coherus BioSciences|CHRS - Company Net Assets|Market Value to Book Value Ratio coherus.com|CHRS - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Coherus Biosciences|CHRS - Long-Term Debt to Equity|Short-Term Debt to Equity Coherus BioSciences, Inc|CHRS - Company Cumulative Debt|Debts to Book Capitalization Coherus BioSciences, Inc.|CHRS - Long-Term Indebtedness|Company Current Liabilities Coherus BioSciences|Quick Liquidity Indicator coherus.com
- net income and valuation multiples indicators:
CHRS - Final Profit|Future Profit Coherus Biosciences|CHRS - Market Price to Net Income Ratio|Forward P/E Multiple Coherus BioSciences|CHRS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Coherus BioSciences, Inc.|CHRS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Coherus BioSciences|CHRS - Earnings per share for the trailing year|Quarterly EPS earnings growth coherus.com|CHRS - Earnings growth in current year
Basic company analysis:coherus.com (CHRS)
Mass-produced product of Coherus BioSciences, Inc

To assess long-term risks, it is critical for investors to track the specific commercial efficiency of the business, as reflected by the rolling year net income per share. Analyzing the trend of the rolling 12-month earnings per share allows for the elimination of quarterly reporting distortions, linking the fundamental profitability of Coherus Biosciences (CHRS) to biosimilar expansion and the optimization of oncology development costs.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Cardiff Oncology, Inc.|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharma CTXR|Net earnings per share for the last 12 months CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months